Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Illumina's "impressive" Q1 resurrects Roche rumors

This article was originally published in Scrip

Executive Summary

Illumina beat analyst estimates in its first fiscal quarter with revenues of $331.0 million (+21%) and non-GAAP earnings of $0.46 per diluted share, ahead of consensus forecasts of $312 million revenue and $0.39-per-share earnings. The Q1 performance, described by analysts as “strong” and “impressive”, raises the possibility of another bid by long-time admirer Roche, which tried and failed to buy Illumina last year. But if Roche does re-enter the fray, it may need to raise its offer, which previously stood at $51 per share, or $6.7 billion in total, and which Illumina rejected as inadequate.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts